BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, Fromm AL, Jørgensen TL, Bjerregaard JK, Hoegdall E, Jensen BV. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncol 2011;50:574-7. [PMID: 21529301 DOI: 10.3109/0284186X.2010.546369] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathol Oncol Res. 2017;23:673-677. [PMID: 28025786 DOI: 10.1007/s12253-016-0166-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
2 Skougaard K, Johannesen HH, Nielsen D, Schou JV, Jensen BV, Høgdall EV, Hendel HW. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. Cancer Med 2014;3:1294-301. [PMID: 24941936 DOI: 10.1002/cam4.271] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]